Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment.
infantile hemangioma
infantile hepatic hemangioma
propranolol
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
28
04
2023
received:
09
10
2022
accepted:
04
05
2023
medline:
4
12
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Infantile hepatic hemangioma (IHH) is a common liver tumor in infants and shares the same characteristics as cutaneous infantile hemangioma (IH). Propranolol is effective for symptomatic IHH. The clinical features between cutaneous IH and IHH, and treatment efficacy of IHH (smaller than 4 cm) is unclear. To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH. The clinical data of infants with complicated cutaneous IH combined with IHH treated with systemic propranolol (1.5 ~ 2 mg/(kg d)) from January 2011 to October 2020 were retrospectively analyzed. Forty-five cases with IHH combined with complicated cutaneous IH were reviewed. Single cutaneous IH is more likely to be combined with focal IHH, cutaneous IH greater than 5, more likely to be combined with multiple IHH (Pearson = 0.546, p < 0.01). The mean age of focal and multiple IHH regression was 11.93 ± 14.42 months and 10.20 ± 9.15 months, respectively. The number of cutaneous IH were correlated with the number of IHH. There was no difference in the age of complete remission for focal and multiple IHH.
Substances chimiques
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3369-3374Subventions
Organisme : Beijing Municipal Natural Science Foundation
Organisme : Chinese Association of Rehabilitation Medicine Scientific Research
Informations de copyright
© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
van Schaijik B, de Jongh J, Marsh RW, Munro M, Itinteang T, Tan ST. Proliferating infantile hemangioma promotes alpha-fetoprotein production by HepG2 cells. Pediatr Res. 2020;87(1):3-6.
Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118(3):882-887.
Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg. 2007;42(1):62-68.
Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg. 2012;47(1):165-170.
Rialon KL, Murillo R, Fevurly RD, et al. Impact of screening for hepatic hemangiomas in patients with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2015;32(6):808-812.
Ji Y, Chen S, Yang K, et al. Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: a multicenter prospective study. J Am Acad Dermatol. 2020;84(5):1378-1384.
Kuroda T, Kumagai M, Nosaka S, et al. Critical infantile hepatic hemangioma: results of a nationwide survey by the Japanese Infantile Hepatic Hemangioma Study Group. J Pediatr Surg. 2011;46(12):2239-2243.
Ernst L, Grabhorn E, Brinkert F, Reinshagen K, Konigs I, Trah J. Infantile hepatic hemangioma: avoiding unnecessary invasive procedures. Pediatr Gastroenterol Hepatol Nutr. 2020;23(1):72-78.
Varrasso G, Schiavetti A, Lanciotti S, et al. Propranolol as first-line treatment for life-threatening diffuse infantile hepatic hemangioma: a case report. Hepatology. 2017;66(1):283-285.
Tian R, Liang Y, Wang J, et al. Propranolol for infantile hepatic hemangioendothelioma: clinical evaluation of drug efficacy and safety using a single-center patient cohort. Ann Hepatol. 2020;19(5):530-534.
Yang K, Peng S, Chen L, Chen S, Ji Y. Efficacy of propranolol treatment in infantile hepatic haemangioma. J Paediatr Child Health. 2019;55(10):1194-1200.
Mahon C, McHugh K, Alband N, et al. Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma. Br J Dermatol. 2021;184(2):340-341.
Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2011;28(3):245-253.
Wang L, Li J, Song D, Guo L. Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. Pediatr Surg Int. 2022;38(8):1149-1155.
Macdonald A, Durkin N, Deganello A, Sellars ME, Makin E, Davenport M. Historical and contemporary management of infantile hepatic hemangioma: a 30-year single-center experience. Ann Surg. 2022;275(1):e250-e255.
Soria EMS, Malla I. Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case. Arch argent pediatr. 2021;119(1):e65-e69.
Yang K, Feng L, Chen S, Ji Y. Progressive infantile hepatic hemangioma not responding to propranolol. J Dermatol. 2019;46(8):e275-e276.
Krivec JL, Lah N, Glušič M, Velikonja O, Paro-Panjan D. Treatment of symptomatic focal hepatic hemangioma with propranolol in neonates: is it efficient? Pediatr Gastroenterol Hepatol Nutr. 2023;26(1):70-77.